Recently, assist cancer detection company Vigilant Biosciences announced that it got another 5 million dollars of B round financing, invested by  White Owl Capital Partners and venVelo. Until now, Vigilant Biosciences has finished the whole B round financing, and the financing amount is about 10.5 million dollars. The company plans to use the new capital for further research and develop more products in the company’s business scope. As early as in 2015, the company received its first financing of 5.5 million dollars, to promote international product launch. Since its inception,  it has financed 12.5 million dollars in total.

Based in Florida, Vigilant Biosciences was founded in 2011. The company’s vision is that through early detection and intervention, it can help reduce patients’ pain in  fighting with later cancer. The company assist medical institutions to offer solutions for early detection and intervention of cancers. It’s a leading innovator and developer in this period. Vigilant Biosciences’OncAlert oral cancer product line and  OncAlert Labs product line can provide timely care at the scene. Furthermore, the products that the company laboratories provide are easily operated, accurate and low-cost to help medical practitioners to assess the risk of oral cancer as early as possible. Through early intervention and corresponding measures, it can improve the potential risk in further development.

Matthew H.J. Kim, Co- founder & Chairman of Vigilant Biosciences said that, “we feel very glad that we can get the B round financing, because it means that our company has successfully transitioned to the commercial stage. In the future, we will provide more breakthrough solutions to assist the medical institutions in early detection and intervention of oral cancer. These financing funds will be able to support us to continue research work in next step, and provide more application for our unique biomarkers technology research and development.”